Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | KDM5C | P41229 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808617 | 0.94 | HDAC1 (0.74) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL2810504 | 0.92 | HDAC1 (0.79) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL29055202 | 0.92 | HDAC1 (0.79) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL2813818 | 0.92 | HDAC1 (0.79) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| Glutarodihydroxamic Acid SCHEMBL11768782 | 0.88 | HDAC1 (0.81) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL27643837 | 0.86 | FOLH1 (0.57) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL137189 | 0.86 | — | — | |
| Ammonia Solution, Strong SCHEMBL2217876 | 0.83 | FOLH1 (0.55) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| Hydrochloric Acid SCHEMBL28102677 | 0.83 | FOLH1 (0.55) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| Fluoride SCHEMBL27659982 | 0.83 | FOLH1 (0.55) | HDAC1HDAC8HDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209504-B1 | DERIVATIZED TERTIARY AMINES AND USES THEREOF | ETHICON INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-7868123-B2 | Derivatized tertiary amines and uses thereof | ETHICON, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| EP-2209504-A2 | DERIVATIZED TERTIARY AMINES AND USES THEREOF | ETHICON, INC. (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-2190845-A2 | HDAC INHIBITORS | ArQule, Inc. (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009026446-A9 | HDAC INHIBITORS | ARQULE, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-7569724-B2 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| EP-2083005-A1 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| WO-2009067491-A2 | DERIVATIZED TERTIARY AMINES AND USES THEREOF | ETHICON, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090131938-A1 | DERIVATIZED TERTIARY AMINES AND USES THEREOF | ETHICON, INC. | 2009-05-21 | — | — | US | disclosed |
| EP-1598067-B1 | Carbamic acid compounds comprising an amide linkage for the treatment of malaria | TOPOTARGET UK LTD (GB) | 2009-05-06 | — | — | EP | disclosed |
| WO-2009026446-A2 | HDAC INHIBITORS | ARQULE, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-1598067-A1 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| EP-1335898-B1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005053610-A2 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2004-05-13 | — | — | US | disclosed |
| EP-1335898-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | Prolifix Limited (GB) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | HDAC5, HDAC1, HDAC4 | HDAC1 2/4885HDAC8 10/4885HDAC6 9/4885 |
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC8 6/4885HDAC6 11/4885 |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC8 6/4885HDAC6 11/4885 |
| US-20090131938-A1 | DERIVATIZED TERTIARY AMINES AND USES THEREOF | SHROOM3, EHMT2, EHMT1 | HDAC1 503/4885HDAC8 2435/4885HDAC6 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.